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ABSTRACT
Purpose To investigate the mechanisms of clearance of
AMG 386, an investigational recombinant peptide-Fc fusion
protein (peptibody) that blocks tumor angiogenesis by neutral-
izing the interaction between angiopoietin-1 and -2 and the
Tie2 receptor.
Methods The role of the neonatal Fc receptor (FcRn) in
AMG 386 clearance was assessed in wild-type and FcRn-
knockout mice; the roles of the spleen and kidneys were
assessed in splenectomized and 5/6th nephrectomized rats,
respectively, compared with sham-operated rats. Animals were
administered AMG 386 as a single intravenous dose of 3 or
10 mg/kg. Blood samples for pharmacokinetic analysis were
collected periodically throughout a 504-hour postdose period.
Results Compared with wild-type mice, AMG 386 clearance
in FcRn-knockout mice was 18-fold faster at the 3-mg/kg dose
(FcRn knockout, 13.2 mL/h/kg; wild-type, 0.728 mL/h/kg) and
14-foldfasteratthe10-mg/kgdose(FcRnknockout,10.7mL/h/kg;
wild-type, 0.777 mL/h/kg). Clearance in nephrectomized rats was
slower than in sham-operated rats at both the 3-mg/kg dose
(nephrectomized, 1.23 mL/h/kg; sham-operated, 1.75 mL/h/kg)
and the 10-mg/kg dose (nephrectomized, 1.14 mL/h/kg; sham-
operated, 1.65 mL/h/kg). Splenectomy had no apparent effect on
the pharmacokinetics of AMG 386.
Conclusions The FcRn is integral to maintaining circulating
levels of AMG 386 in mice. Renal clearance contributed ap-





AUC area under the concentration versus time curve
AUC0–∞ area under the serum concentration versus
time curve from time 0 to infinity
AUC0–last area under the serum concentration versus
time curve from time 0 to the last quantifiable
concentration
AUMC area under the first moment of the
concentration versus time curve
C0 concentration at time 0
CL clearance
Clast last quantifiable concentration
ELISA enzyme-linked immunosorbent assay




LLOQ lower limit of quantitation
t½,z estimated terminal elimination half-life
TMDD target-mediated drug disposition
V0 initial volume of distribution
Vss volume of distribution at steady state
INTRODUCTION
Peptibodies are novel fusion proteins that combine an anti-
body Fc domain and at least one biologically active peptide
domain (1). These peptide-Fc fusion proteins have markedly
improved pharmacokinetics compared with simple peptides
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DOI 10.1007/s11095-011-0650-z(1). They also have significant potential as therapeutic agents,
as evidenced by the recent approval of romiplostim for the
treatmentofimmunethrombocytopenicpurpura(2).However,
the mechanisms of clearance for peptibodies are not well un-
derstood. Understanding these mechanisms is a particularly
importantconsiderationintheoncologysetting,wheredifferent
therapeutic agents are routinely combined and where there is
potential for significant toxicity as a consequence of increased
exposure owing to drug-drug interactions (3). Clearance and
drug exposure are also important considerations in terminally
ill patients, who often have comorbid conditions, such as im-
paired renal function (4), that can alter the pharmacokinetics of
pharmacologic agents. Thus, further investigation of clearance
mechanisms for peptibodies intended to treat cancer is impor-
tant because it may improve the understanding of relation-
ships between dose, pharmacokinetic exposure, and
pharmacodynamic response (5).
The clearance of small molecular therapeutics is depen-
dent in large part on their biotransformation (in particular
their metabolism by the cytochrome P450 enzymes) (6), but
a different set of processes are involved in the clearance of
therapeutic proteins (7). For antibodies bearing the immu-
noglobulin G (IgG) Fc domain, a key determinant of their
pharmacokinetic properties is their interaction with the neo-
natal Fc receptor (FcRn), which allows for their salvage and
recycling by the reticuloendothelial system (8–11). Recent
evidence has supported the hypothesis that the FcRn also
regulates clearance of peptide-Fc fusion proteins bearing an
IgG Fc domain (12,13). Tissues that have been demonstrat-
ed to be involved in the clearance of IgG include the spleen
(14,15) and kidney (16,17). Finally, clearance by high-
affinity binding to their target (ie, target-mediated drug
disposition [TMDD]) (18) may also contribute to the clear-
ance of peptibodies; TMDD has been reported to account
for a significant portion of clearance of romiplostim (13).
AMG 386, a peptide-Fc fusion protein with a molecular
weight of 63.5 kilodaltons (kDa), is an investigational pepti-
body that blocks tumor angiogenesis by selectively neutral-
izing the interaction between angiopoietin-1 and -2 (Ang1
and Ang2) and their receptor, Tie2 (19,20). In preclinical
studies, AMG 386 significantly inhibited vascular endothe-
lial growth factor–stimulated neovascularization in a corne-
al angiogenesis model and had antitumor activity against
established tumor xenografts (19). Importantly, in Colo205
colon cancer tumor xenograft models, inhibition of both
Ang1 and Ang2 demonstrated superior tumor growth sup-
pression compared with inhibition of Ang1 or Ang2 alone
(21). In phase 1 clinical studies, AMG 386 has shown prom-
ising antitumor activity and was well tolerated in patients
with advanced solid tumors when administered as a mono-
therapy (20) or in combination with various chemotherapy
regimen (20,22). Among patients with recurrent ovarian
cancer, administration of AMG 386 10 mg/kg QW plus
weekly paclitaxel resulted in acceptable toxicity and encour-
aging estimated progression-free survival time compared
with placebo plus paclitaxel (23). The pharmacokinetics of
AMG 386 are linear between 0.3 and 30 mg/kg (the max-
imum tested dose in the first-in-human study) when admin-
istered as a monotherapy in patients with solid tumors (20).
The pharmacokinetics of AMG 386 do not appear to be
altered when combined with chemotherapy regimens, in-
cluding paclitaxel, docetaxel, carboplatin/paclitaxel, and
FOLFOX (oxaliplatin, leucovorin, and 5-fluorouracil)
(22,23). Moreover, population pharmacokinetic analyses
have shown that creatinine clearace is an important cova-
riate affecting AMG 386 total clearance in cancer patients,
suggesting that renal clearance may play a key role in
AMG 386 disposition (24). Here, we describe results from
experiments conducted in rodent models that investigated
the mechanisms of clearance of AMG 386. Specifically, we
examined the role of the FcRn in AMG 386 recycling and




AMG 386 was manufactured by Amgen Inc. (Thousand
Oaks, CA). For each experiment, AMG 386 was diluted
with vehicle (3.4% [weight/volume] arginine HCI, 10 mM
potassium phosphate, 0.004% polysorbate 20; pH 7.0) to
achieve the concentrations required for dosing.
Animal Models
All experiments involving animals were performed at
Amgen Inc. All study procedures were consistent with the
National Resource Council’s Guide for the Care and Use of
Laboratory Animals (25) and the guidelines of the Association
for Assessment of Laboratory Animal Care (Frederick, MD),
and were approved by the Amgen Animal Care and Use
Committee. Animals were maintained in a 12-hour light/
dark cycle environment. Food and water were available ad
libitum throughout the experiments.
FcRn Knockout Mouse Models
W i l d - t y p em a l em i c e( C 5 7 B L/6J strain), and FcRn-
knockout male mice (B6.129P2-B2m
tm1Unc/J strain) were
purchased from Jackson Laboratories (Bar Harbor, ME).
Animals were 6 to 14 weeks of age and weighed between
17 and 40 g on the first day of dosing. AMG 386 was
administered as a single intravenous (IV) bolus dose via
the lateral tail vein to 78 FcRn-knockout mice and 78
1058 Wu et al.wild-type mice at arbitrarily assigned doses of 3 mg/kg or
10 mg/kg (n039 per group). The composite blood sampling
design used 3 mice per group per time point, and samples
were obtained via terminal bleed before dosing and at 0.25,
1, 4, 12, 24, 48, 96, 168, 240, 336, 432, and 504 h postdose.
An enzyme-linked immunosorbent assay (ELISA) with a
lower limit of quantitation (LLOQ) of 39.1 ng/mL was used
to measure AMG 386 concentrations in the serum (see
Assessment of Serum AMG 386 Concentrations).
Splenectomized and Nephrectomized Rat Models
Male Sprague–Dawley rats (350 to 425 g) were
obtained from Charles River Laboratories (Hollister,
CA). In each experiment, 16 rats were anesthetized with
isoflurane (Abbott Laboratories, North Chicago, IL).
Aseptic surgical technique was used in all surgical pro-
cedures. For splenectomy experiments, the spleen was
removed from 8 rats (splenectomized rats) and gently
manipulated in 8 other rats (sham-operated rats) 1 to
2 days before dosing. For subtotal (5/6th) nephrectomy
experiments, blood flow to two thirds of the left kidney
was blocked by ligating two of the three branches of the
renal artery before the kidney was placed back into the
abdomen. Following a 1-week postoperative recovery
period, the entire right kidney was also removed and
the rats underwent an additional 1-week postoperative
recovery period. In 8 sham-operated rats, the left and
right kidneys were gently manipulated in the same se-
quence as described for nephrectomized rats. Each ex-
periment also included 8 rats in a control group that
did not undergo any surgical procedures. Following
postoperative recovery, splenectomized, nephrectomized,
or sham-operated animals received a single bolus dose
of IV AMG 386 3 mg/kg or 10 mg/kg (n04p e rd o s e
group). Blood samples were collected from the jugular
vein or the lateral tail vein predose and at 0.25, 1, 4,
12, 24, 48, 96, 168, 240, 336, 432, and 504 h postdose
for pharmacokinetic assessment. For all samples from
splenectomized and nephrectomized animals, an ELISA
with an LLOQ of 78.1 ng/mL was used to measure
AMG 386 concentrations in the serum (see Assessment of
Serum AMG 386 Concentrations).
Assessment of Serum AMG 386 Concentrations
Quantification of AMG 386 concentrations in mouse and
rat serum was performed by ELISA. Human Ang2 was
adsorbed onto flat-bottom 96-well polystyrene microtiter
plates. Uncoated areas of the plates were blocked with I-
Block Buffer (Applied Biosystems, Foster City, CA), and the
plates were washed to remove unbound material. Stand-
ards, quality controls, and study samples were diluted 1:50
in I-Block Buffer containing 3% bovine serum albumin and
dispensed into duplicate wells. After washing with 1× KPL
wash buffer (KPL, Inc., Gaithersburg, MD), a horseradish
peroxidase–labeled murine anti-human IgG1 (Fc) monoclo-
nal antibody (Amgen Inc.) was added to the wells. A final
wash step with 1× KPL wash buffer was performed to
remove unbound materials before addition of a substrate
solution containing hydrogen peroxide and 3, 3′,5 ,5 ′-
tetramethylbenzidine, which produced a colorimetric signal
proportional to the amount of bound AMG 386. The
colorimetric reaction was stopped by addition of 2N
sulfuric acid, and optical density was measured at
450 nm (OD450) with a reference wavelength of
650 nm. Conversion of OD450 to AMG 386 concentra-
tion was performed by reference to a concurrently an-
alyzed standard curve using a logistic regression model
with a weighting factor of 1/Y
2 and the Watson data
reduction package version 7.0.0.01 (Thermo Fisher Scientific,
Pittsburgh, PA).
Pharmacokinetic Analyses
Pharmacokinetic parameters were calculated using standard
noncompartmental methods in WinNonlin Professional ver-
sion 4.1e (Pharsight Inc., Mountain View, CA). The con-
centration at time zero (C0) was estimated via linear back-
extrapolation to time zero using the first two time points.
The area under the serum concentration versus time curve
(AUC0–last) was calculated from time zero to the last quan-
tifiable concentration (Clast). The rate constant of the termi-
nal phase (λ) was calculated via linear regression of the log-
linear decay of the terminal phase using at least the last
three time points with detectable serum concentrations.
Extrapolation of the area under the serum concentration
versus time curve to infinity (AUC0–∞) was estimated as the
sum of corresponding AUC0–last and Clast/λ values. System-
ic clearance was calculated as the dose divided by AUC0–∞.
Terminal half-lives were calculated as 0.693/λ. The initial
volume of distribution (V0) was calculated as Dose/C0. The
volume of distribution at steady state (Vss ) was calculated as
Dose•AUMC0–∞/(AUC0–∞)
2, in which AUMC is the area
under the first moment of the concentration versus time
curve.
SAS version 9.2 was used to perform statistical com-
parisons of log-transformed pharmacokinetic parameters.
Pharmacokinetic parameters from nephrectomized and
splenectomized rats were compared with the PK param-
eters of the respective sham-operated animals. The p
value for the comparison between treatment group and
sham-operated control as well as the ratio associated
with this comparison and its 95% confidence interval
are reported. Statistical significance was defined as p
values of less than 0.05.
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Pharmacokinetics of AMG 386 in FcRn-Knockout
Versus Wild-Type Mice
In wild-type mice, AMG 386 exhibited a biexponential dispo-
sition profile with a fast distribution phase followed by a
prolonged elimination phase after a single IV administration
of 3 or 10 mg/kg of AMG 386. Using the same doses in FcRn-
knockout mice, there was a monoexponential decline in serum
AMG 386 concentrations with a markedly faster elimination
rate than that occurring in wild-type mice (Fig. 1). The phar-
macokinetic parameters of AMG 386 measured in both experi-
ments are summarized in Table I. AMG 386 clearance after 3-
and 10-mg/kg doses was markedly faster (approximately 18-
and 14-fold, respectively) in the FcRn-knockout mice com-
pared with wild-type animals. Clearance values ranged from
0.728 mL/h/kg (3 mg/kg) to 0.777 mL/h/kg (10 mg/kg) in
the wild-type mice and from 13.2 mL/h/kg (3 mg/kg) to
10.7 mL/h/kg (10 mg/kg) in FcRn-knockout mice. The Vss
for FcRn-knockout mice was 2- to 3-fold lower than for wild-
type animals. The mean half-life was approximately 5 h for
knockout mice and approximately 150 h (6 days) for wild-type
mice.
Pharmacokinetics of AMG 386 in Splenectomized,
Sham-Operated, and Control Rats
The pharmacokinetics of AMG 386 demonstrated a biex-
ponential disposition profile in each of the three groups of
animals. In general, the pharmacokinetic parameters of
AMG 386 in splenectomized rats were not statistically sig-
nificantly different from those in control rats (which under-
went no surgical procedures) or sham-operated rats (p>0.05).
The AMG 386 concentration versus time profiles were also
similar across animal groups (Fig. 2). Likewise, the serum
AMG 386 exposure was comparable in sham-operated, sple-
nectomized, and control rats following administration of 3 or
10 mg/kg of AMG 386 (Table II). Serum exposure appeared
to be dose-proportional across the two tested doses of AMG
386 (3 and 10 mg/kg), with 3.4- to 4.4-fold higher C0 and
AUC values observed at the higher dose (Table II). Further-
more, AMG 386 clearance in control rats was similar at both
AMG 386 doses, indicating that AMG 386 elimination fol-
lowed linear kinetics. The estimated half-life for AMG 386
ranged from 78 to 97 h for the 3-mg/kg dose and from 91 to
118 h for the 10-mg/kg dose.
Pharmacokinetic Profile of AMG 386
in Nephrectomized, Sham-Operated, and Control Rats
As in the splenectomy experiments, AMG 386 had a biex-
ponential disposition profile with a fast distribution phase
and a prolonged elimination phase in each of the three
experimental groups. AMG 386 exposure increased in an
approximately dose-proportional manner in nephrectom-
ized, sham-operated, and control rats after a single IV dose
of 3 or 10 mg/kg of AMG 386 (Fig. 3). At both doses,
clearance was approximately 30% lower in the nephrectom-
ized animals compared with those in the control and sham-
operated groups (Table III). Nephrectomized rats had
higher exposure (AUC0–∞) compared with the control and
sham-operated animals. The mean AMG 386 half-life
ranged from 86.6 to 88.6 h in nephrectomized rats, com-
pared with a range of 105 to 125 h for sham-operated rats
and 112 to 116 h for control rats. Relevant pharmacokinetic
parameters (CL and VSS) were statistically significantly dif-
ferent (p<0.05) when comparing data from nephrectomized
rats with those obtained from sham-operated animals. Dose
linearity appeared to be maintained across both doses, indi-
cating that the contribution of the kidneys to AMG 386 clear-
ance did not change with increasing dose (3 and10 mg/kg).
DISCUSSION
Currently, the mechanisms of clearance of peptibodies are
not extensively characterized. Recently, population phar-
macokinetic analysis of the investigational peptibody
AMG 386, a selective inhibitor of Ang1 and Ang2 (19),
using data from patients with advanced solid tumors (20)
and patients with recurrent ovarian cancer (23)r e v e a l e d
that clearance of the molecule was significantly associated
with creatinine clearance (24). In the present study, we
assessed the clearance mechanisms of AMG 386 in three
specialized rodent models. In FcRn knockout mice, clear-
ance of AMG 386 was increased 14- to 18-fold compared
with wild-type animals. In rats, the kidneys accounted for
approximately 30% of AMG 386 clearance, whereas the
Time Postdose, h


















































1000 10 mg/kg wildtype (n=3/timepoint)
10 mg/kg knockout (n=3/timepoint)
3 mg/kg wildtype (n=3/timepoint)
3 mg/kg knockout (n=3/timepoint)
Fig. 1 Pharmacokinetic profile of AMG 386 in wild-type and FcRn-
knockout mice following a single intravenous dose of 3 or 10 mg/kg.
1060 Wu et al.spleen did not appear to contribute to the total clearance of
AMG 386.
There was no evidence of dose-dependent changes in the
pharmacokinetic characteristics of AMG 386 when 3-
and 10-mg/kg doses of AMG 386 were administered
intravenously to wild-type and knockout mice, implying
that FcRn is a large reservoir that cannot be easily
saturated. Furthermore, the lack of dose dependency at
the two tested doses suggests that TMDD does not play
an important role in the clearance of AMG 386. This is
consistent with the linear pharmacokinetics observed in
the first-in-human monotherapy study in which the
clearance of AMG 386 was similar (1.17 mL/h/kg)
across a wide range of administered AMG 386 doses
(0.3 to 30 mg/kg) (20). A lack of TMDD for AMG 386
was not unexpected given that it binds to circulating
Ang1 and Ang2. In contrast, romiplostim (which exhibits
TMDD) binds to cell surface c-Mpl receptors which may
result in internalization and degradation of the protein com-
plex(13).These differencesindicate thatmechanismsofclear-
ance may vary markedly between peptibodies.
Moreover, they underline the importance of studies such
as the present one, that allow an early assessment of the
clearance mechanisms of novel, investigational peptibodies.
The results of our study demonstrate that the FcRn plays
a crucial role in the disposition of AMG 386. The Fc
domain portion of peptibodies interacts with the FcRn,
which presumably prevents them from undergoing lysosomal
degradation following cellularpinocytosis,therebyprolonging
their circulating half-life (10). Although human FcRn
interacts with the Fc domain of IgG in a species-specific
manner, residues on FcRn responsible for IgG binding in
mice are conserved across species (26), making the murine
model appropriate for peptibody-FcRn interaction assess-
ment. The clearance rates of AMG 386 were approximately
18- and 14-times faster in the FcRn-knockout mice compared
with those in wild-type animals following single IV doses of 3
and 10 mg/kg of AMG 386, respectively. The magnitude of
the clearance increase for AMG 386 between wild-type and
FcRn-knockout mice is comparable to that reported in
previous studies using IgG or the peptibody romiplostim
(approximately 10- to 24-fold increases in clearance)
(9,10,13,27,28). Using noncompartmental methods, the
estimated Vss was 2- to 3-fold lower in FcRn-knockout
micecompared with wild-type animals. However, the true Vss
cannot be estimated for FcRn-knockout mice because the
fusion protein may be distributed to the tissues and may
undergo lysosomal catabolization rather than redistribution
to the central compartment. The half-life of AMG 386 in
wild-type mice was similar to the reported half-life of IgG1
(6.25 vs 5 days) (27), highlighting the advantageousness of
retaining the antibody Fc domain in peptibodies.
The pharmacokinetic characteristics of AMG 386 (at
doses of 3 or 10 mg/kg) were not altered in splenectomized
rats compared with sham-operated or control animals.
These results demonstrate that the spleen plays a small role
in the clearance of AMG 386 and suggest that the rat spleen
contains low levels of FcRn. A study in splenectomized
humans reported no splenic involvement in the elimination
of
123I-labeled IgG but instead, an increased uptake of IgG
by the liver, which compensated for the loss of spleen
Table I Pharmacokinetic Parameters of AMG 386 After a Single Intravenous Dose of 3 or 10 mg/kg of AMG 386 in Wild-Type or FcRn-Knockout Mice
Parameter Wild-Type (n039, 3 per time point) FcRn-Knockout (n039, 3 per time point)
AMG 386 3 mg/kg AMG 386 10 mg/kg AMG 386 3 mg/kg AMG 386 10 mg/kg
C0, μg/mL 65.1 227 74.9 246
AUC0–last, μg￿h/mL 3730 11,800 223 931
AUC0–∞, μg￿h/mL 4120 12,900 227 932
t1/2,z, h 152 149 4.46 5.31
CL, mL/h/kg 0.728 0.777 13.2 10.7
V0, mL/kg 46.1 44.1 40.1 40.7






1000 3 mg/kg control (n=4)
3 mg/kg sham (n=4)
3 mg/kg splenectomized (n=3–4)
10 mg/kg control (n=3–4)
10 mg/kg sham (n=3–4)
10 mg/kg splenectomized (n=4)
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Fig. 2 Pharmacokinetic profile of AMG 386 in control (no surgical pro-
cedures), sham-operated, and splenectomized Sprague–Dawley rats fol-
lowing a single intravenous dose of 3 or 10 mg/kg.
Mechanism of Clearance of AMG 386 in Rodent Models 1061function (29). Because of the general lack of cytochrome
P450 enzyme involvement in protein metabolism, the contri-
bution of the liver to the elimination of AMG 386 was not
evaluated. Additionally, because the incidence of anti-
AMG 386 antibody formation in humans is low (20), it was
not anticipated that immunogenicity would play a significant
role in the elimination of the molecule.
In the absence of TMDD and spleen involvement, the
kidneys can play an important role in elimination of Fc-
containing macromolecules, secondary to FcRn recycling
(16,17). In the present study, we found that the clearance
of AMG 386 in nephrectomized rats was decreased by
approximately 30% compared with control and sham-
operated rats, indicating that the kidneys contributed
approximately 30% to catabolism and/or elimination
of the total administered dose of AMG 386. In similar
studies using the peptibody romiplostim, exposure was
increased by 26% to 80% in nephrectomized rats compared
with control animals (13). Although extrapolation of these
data from rats to humans has inherent limitations, it should
be noted that the pharmacokinetic profile of AMG 386 in the
rat is closer to that of humans than any other species tested
(Amgen Inc., data on file). The Vss values of nephrectomized
rats were also stastistically significantly lower (p<0.05)
than the values obtained from sham-operated rats.
However, the noncompartmental approach assumes that
the drug elimination occurs only from the central com-
partment, which conflicts with the accepted finding that
antibodies are catabolized in extravascular tissues (30).
Thus, without directly measuring tissue concentrations, the
interpretation ofVssfor protein therapeuticsisusually limited.
The glomerular sieving coefficient (GSC), an indicator of
the rate of renal filtration of a molecule, is likely to be
relatively low for peptibodies. The GSC is affected by nu-
merous biochemical properties including molecular weight,
size, charge, lipophilicity, and affinity with opsonization
factors (31). The molecular weight of AMG 386 is slightly
lower than that of albumin (63.5 vs 69 kDa), which has a
GSC of 0.001 (32). Therefore, it is reasonable to speculate
that fusion proteins are also filtered by the kidneys, although
not efficiently. Nonetheless, given the high perfusion rate of
kidneys and the long half-life of AMG 386, renal clearance
may still play an important role in the overall clearance of
AMG 386.
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C0, μg/mL 60.4 (3.55) 275 (19.2) 69.1 (9.56) 237 (42.4) 59.6 (29.2) 235 (14.8) 0.431 0.88 (0.63–1.23)
AUC0–last, μg￿h/mL 1420 (68.2) 5410 (543) 1600 (132) 5470 (830) 1320 (240) 5850 (451) 0.381 0.94 (0.80–1.09)
AUC0–∞, μg￿h/mL 1460 (70.0) 5540 (570) 1630 (127) 5620 (770) 1340 (238) 5970 (445) 0.336 0.93 (0.81–1.08)
t1/2,z, h 97.4 (14.4) 118 (4.50) 86.0 (13.4) 91.4 (31.8) 77.9 (13.0) 107 (7.79) 0.650 1.05 (0.83–1.33)
CL, mL/h/kg 2.06 (0.095) 1.82 (0.197) 1.85 (0.15) 1.80 (0.244) 2.29 (0.4) 1.68 (0.129) 0.336 1.07 (0.93–1.24)
V0, mL/kg 49.8 (2.96) 36.5 (2.66) 44.0 (5.61) 43.4 (9.28) 65.9 (45.5) 42.6 (2.63) 0.431 1.14 (0.81–1.59)
Vss, mL/kg 185 (20.2) 170 (10.2) 152 (14.7) 149 (23.8) 175 (40.7) 158 (16.7) 0.222 1.10 (0.94–1.29)
CI confidence interval
aAll data are mean (SD)
bControl animals underwent no surgical procedures
cOne animal was excluded owing to a suspected error in dose administration
dStatistical comparisons of splenectomized versus sham-operated groups at 3 and 10 mg/kg of AMG 386; P<0.05 was considered statistically significant
3 mg/kg control (n=3)
3 mg/kg sham (n=3)
3 mg/kg nephrectomized (n=4)
10 mg/kg control (n=4)
10 mg/kg sham (n=4)




















































Fig. 3 Pharmacokinetic profile of AMG 386 in control (no surgical pro-
cedures), sham-operated, and nephrectomized Sprague–Dawley rats fol-
lowing a single intravenous dose of 3 or 10 mg/kg.
1062 Wu et al.The excretion of AMG 386 in the urine was not directly
measured because of assay limitations. A biodistribution
study of
125I-labeled AMG 386 in cynomolgus monkeys
showed that, although most of the administered radioactivity
was collected in the urine and cage rinse, <10% of it was
incorporated in intact protein based on trichloroacetic acid
precipitation assays (Amgen Inc., unpublished data). Present-
ly, it is unknown what proportion of AMG 386 is excreted
intact via the kidney. A clinical study in cancer patients with
either normal or impaired renal function has been initiated to
evaluate the effect of differences in estimated glomerular
filtration rates on the pharmacokinetics of AMG 386
(ClinicalTrials.gov, NCT01331941).
Based on the data collected in the experiments with
FcRn-knockout mice, the main determinant of AMG 386
disposition appears to be FcRn recycling. Furthermore,
Sarav et al. (17) have shown that FcRn is expressed on
podocytes and the brush border of the proximal tubular
epithelium in murine kidneys, and that renal FcRn plays a
role in the metabolism of albumin and IgG. This observa-
tion is consistent with a previously proposed mechanism of
FcRn protection and clearance for IgG molecules, including
monoclonal antibodies (10,30). However, the exact FcRn
association and dissociation characteristics of various types
of protein therapeutics are presently unknown. Future
exploration to elucidate the rate-limiting factors that could
contribute to a prolonged half-life would be of interest.
While the experiments described herein show that renal
clearance contributed to approximately 30% of the total
clearance of AMG 386 in rats, other clearance mechanisms
must account for the remainder. Although a comprehensive
understanding of all pathways of clearance for biologic
therapeutics requires future research, it is generally accepted
that most of them undergo nonspecific catabolism, similar to
endogenous and dietary proteins (33). This includes nonspe-
cific proteolytic catabolism following endocytosis by endo-
thelial cells and hepatic protein metabolism (34). Although
the cytochrome P450 system does not play a role in metab-
olism of biologic therapeutics, alternative pathways that
allow efficient uptake and catabolism of exogenous proteins
are present in hepatocytes (34,35). Additionally, because
FcRn plays a central role in regulating the half-life of pepti-
bodies, variation in FcRn binding affinity could potentally
affect the clearance of these molecules as has been demon-
strated for other IgG1 molecules (36). Development of im-
munogenicity may also influence the clearance of protein
therapeutics. Even when a recombinant human protein
molecule has nearly identical sequence to an endogenous
protein, anti-drug antibodies have been shown to influence
the clearance of peptibodies including those containing
sequences nearly identical to endogenous proteins (30,37).
However, in clinical studies, the incidence of immunogenic-
ity to AMG 386, assessed using a highly specific assay, was
low (20,22,38,39); thus it appears unlikely that immunoge-
nicity contributes substantially to the clearance of AMG
386. In summary, although we have explored the involve-
ment of FcRn, spleen, and kidneys in the clearance of AMG
386, understanding the exact contributions of other rate-
limiting factors to the clearance of AMG 386 and other
peptibodies will require further investigation.


























C0, μg/mL 68.9 (6.82) 258 (15.1) 65.3 (16.3) 241 (23.9) 66.2 (16.2) 226 (11.8) 0.7662 0.97 (0.80–1.18)
AUC0–last,
μg￿h/mL
1670 (204) 6290 (489) 1700 (238) 5880 (287) 2440 (319) 8530 (665) <0.0001 1.39 (1.22–1.59)
AUC0–∞,
μg￿h/mL
1730 (230) 6480 (530) 1730 (246) 6060 (285) 2480 (308) 8830 (659) <0.0001 1.39 (1.22–1.58)
t1/2,z, h 112 (9.26) 116 (39.2) 105 (4.72) 125 (7.84) 88.6 (15.6) 86.6 (28.0) 0.012 0.68 (0.51–0.91)
CL, mL/h/kg 1.77 (0.242) 1.55 (0.119) 1.75 (0.241) 1.65 (0.0799) 1.23 (0.174) 1.14 (0.0876) <0.0001 0.72 (0.63–0.82)
V0, mL/kg 43.8 (4.51) 38.9 (2.29) 48.2 (13.4) 41.8 (4.58) 48.1 (15.1) 44.2 (2.34) 0.7662 1.03 (0.84–1.25)
Vss, mL/kg 171 (9.64) 164 (22.8) 167 (18.1) 175 (11.3) 136 (27.3) 120 (22.7) 0.0003 0.72 (0.62–0.84)
CI confidence interval
aAll data are mean (SD)
bControl animals underwent no surgical procedures
cOne animal was excluded owing to a suspected error in dose administration
dStatistical comparisons of nephrectomized versus sham-operated groups at 3 and 10 mg/kg of AMG 386; P<0.05 was considered statistically significant
Mechanism of Clearance of AMG 386 in Rodent Models 1063CONCLUSIONS
In summary, the peptibody AMG 386 demonstrated linear
pharmacokinetic properties after single-dose administration
as monotherapy in mice and rats, and no evidence of
TMDD was apparent. The FcRn appeared to be a key
contributor to the long half-life of AMG 386. In rats, no
involvement of the spleen in AMG 386 elimination was
observed, but the kidneys accounted for approximately
30% of AMG 386 clearance. Although the GSC for AMG
386 is expected to be low, the kidney may still play an
important role in AMG 386 clearance because of the long
half-life of the drug and the kidneys’ high perfusion rate.
Renal drug-drug interaction at the transporter level is not
expected, but renal impairment may play a role in fusion
protein clearance. Currently, the US Food and Drug Ad-
ministration recommends that renal impairment studies be
conducted for drugs with substantial renal elimination
(ie, ≥30% of agent excreted in urine unaltered) (40). A clinical
studytoevaluatethepharmacokineticsofAMG386incancer
patients withvaryinglevelsofrenalfunctionhasbeeninitiated
(ClinicalTrials.gov, NCT01331941). Overall, the results of
the study described herein provide valuable insight into the
pharmacokinetic characteristics of peptibodies, a group of
molecules that has yet to be studied in detail.
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